@entity7766 has been recently characterised as one of the strongest circulating vasoconstrictor peptides, its elevated level may cause @entity3361 and increase of peripheral vascular resistance. All this contributes to @entity63 @entity296 and decrease of regional and global left ventricular function. The aim of the study was the examination of @entity7766 plasma levels in @entity1 with @entity583 ( @entity583 ) after thrombolytic therapy with or without reperfusion. The survey was made in 82 @entity1 with @entity583 after thrombolytic therapy: 40 of them without reperfusion and 42 with reperfusion. The control group consisted of 20 healthy @entity1 . Plasma levels of @entity7766 were measured before thrombolysis, then 1, 3 and 5 days after, using a radioimmunologic method. All @entity1 were treated with @entity117 , @entity1242 and thrombolytic therapy (TT) with alteplase (r-TPA). In @entity1 with @entity583 , @entity7766 plasma levels were normal before and 1 day after TT, and were significant elevated 3 days after TT 5 days after TT, plasma @entity7766 levels were still high in @entity1 without reperfusion, but they decreased in @entity1 with reperfusion. There was significant negative correlation between @entity7766 level and left ventricular ejection fraction measured 5 days after @entity583 . During 30-days follow up @entity299 of left ventricle with ejection fraction under 40% occurred in 21 @entity1 and in 11 of them clinical symptoms of @entity712 were observed. Using the multivariable regression analysis we showed that @entity7766 concentration over 60 pg/ml is the independent factor leading to @entity299 . The results of our study suggest the contribution of @entity7766 to the left ventricular remodeling after @entity583 .

[Plasma levels of neuropeptide Y i @entity1 with current XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients', 'persons'] @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial damage'] @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity7766 :: ('4852', 'Gene') :: ['NPY', 'Neuropeptide Y (NPY)'] @entity1242 :: ('MESH:D005996', 'Chemical') :: ['glyceryl trinitrate'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity3361 :: ('MESH:D003329', 'Disease') :: ['coronary artery spasm'] @entity299 :: ('MESH:D006331', 'Disease') :: ['systolic dysfunction', 'left ventricle systolic dysfunction'] @entity583 :: ('MESH:D009203', 'Disease') :: ['AMI', 'acute myocardial infarction']
@entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']
